Actinium Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ATNM research report →
Range $4 – $24.26
Price Chart
About the company
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing and commercializing treatments, primarily focusing on those for bone marrow transplant (BMT) or other cellular and adoptive cell therapies. Its leading drug candidate, I-131 apamistamab (known as Iomab-B), is currently in a crucial Phase III clinical trial for its role in conditioning elderly patients with relapsed or refractory acute myeloid leukemia prior to BMT.
- CEO
- Sandesh C. Seth
- IPO
- 2012
- Employees
- 27
- HQ
- New York City, NY, US
Get TickerSpark's AI analysis on ATNM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $35.14M
- P/E
- 3.11
- Fwd P/E
- 0.70
- PEG
- 0.01
- P/S
- 1.00
- P/B
- 1.16
- EV/EBITDA
- 0.00
- Div Yield
- 0.00%
- Gross Margin
- 101.13%
- Op Margin
- 27.23%
- Net Margin
- 32.23%
- ROE
- 83.42%
- ROIC
- 30.20%
Latest fiscal year · YoY change
- Revenue
- $90.00K+0.0%
- Gross Profit
- $90.00K+111.1%
- Op Income
- $-36,247,000
- Net Income
- $-33,887,000+11.4%
- EPS
- $-1.09+14.2%
- OCF Growth
- +25.7%
- FCF Growth
- +25.4%
- 52W High
- $1.81
- 52W Low
- $0.73
- 50D MA
- $0.94
- 200D MA
- $1.18
- Beta
- 0.02
- RSI (14)
- 71
- Avg Volume
- 139.36K
No earnings-call transcripts are available for ATNM yet.
- Free Float
- 99.4%
- Shares Outstanding
- 31.37M
- Float Shares
- 31.19M
of shares held by institutions
62 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 1.42M | ▲ 36.49K |
| Two Sigma Advisers, LP | 196.08K | ▼ 300 |
| Avantax Advisory Services, Inc. | 14.49K | 0 |
| Point72 Asia (Singapore) Pte. Ltd. | 10.29K | ▼ 10.75K |
| Cwm, LLC | 351 | ▼ 269 |
| Cubist Systematic Strategies, LLC | 1 | ▼ 1.93K |
Held by 22 ETFs
Biggest fund positions in ATNM by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 18, 25 | SETH SANDESH | other | 120,900 |
| Mar 31, 25 | Steinhart Richard I | sell | 72,156 |
| Mar 31, 25 | Steinhart Richard I | sell | 8,333 |
| Mar 31, 25 | Steinhart Richard I | sell | 2,500 |
| Mar 31, 25 | Steinhart Richard I | sell | 2,500 |
| Mar 31, 25 | Steinhart Richard I | sell | 70,311 |
| Mar 31, 25 | Steinhart Richard I | sell | 18,351 |
| Mar 31, 25 | Steinhart Richard I | sell | 8,333 |
| Mar 31, 25 | Steinhart Richard I | sell | 2,500 |
| Mar 31, 25 | Chell Jeffrey W. | sell | 2,500 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ATNM coverage
Recent articles, reports, and earnings notes.
No research on ATNM yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ATNM report →Actinium Pharmaceuticals Announces Actimab-A Intellectual Property and Manufacturing Advances and Provides NYSE American Listing Update
prnewswire.com · Aug 14
Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) vs. Actinium Pharmaceuticals (NYSE:ATNM) Financial Contrast
defenseworld.net · Jul 30
Palatin Technologies (OTCMKTS:PTNT) and Actinium Pharmaceuticals (NYSE:ATNM) Head to Head Review
defenseworld.net · Jul 26
Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer
prnewswire.com · Jun 3
Actinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Prostate Cancer Models
prnewswire.com · Jun 3
Actinium Appoints Accomplished Oncology Expert Steffen Heeger MD, MSc as Chief Medical Officer to Drive Rejuvenated Pipeline Development
prnewswire.com · Jun 1
Actinium Pharmaceuticals Presents New Radiochemistry Data at SNMMI 2026 Demonstrating That CAR Optimization Improves Tumor Targeting and Pharmacokinetics of Actinium-225 Radioconjugates
prnewswire.com · Jun 1
Actinium Pharmaceuticals Receives Two Patent Allowances Spanning Its Actimab-A and Iomab-ACT Programs
prnewswire.com · May 29
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.